EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudiePragmatische StudieOpen Access

Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure

Robert J Mentz, Kevin J Anstrom, Eric L Eisenstein, Shelly Sapp, Stephen J Greene, Shelby Morgan, Jeffrey M Testani, Amanda H Harrington, Vandana Sachdev, Fassil Ketema, Dong-Yun Kim, Patrice Desvigne-Nickens und 3 weitere

JAMA · 17.01.2023 · 329 (3) · 214

DOI: 10.1001/jama.2022.23924 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA, erschienen am 17.01.2023. Verfasst von Robert J Mentz und 14 weiteren Autor:innen. Beteiligte Einrichtung: Duke Clinical Research Institute, Durham, North Carolina. Hauptthemen laut MEDLINE: Furosemide, Heart Failure. Die Arbeit wurde bisher 183-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Although furosemide is the most commonly used loop diuretic in patients with heart failure, some studies suggest a potential benefit for torsemide.

Objective

To determine whether torsemide results in decreased mortality compared with furosemide among patients hospitalized for heart failure. Design, Setting, and Participants TRANSFORM-HF was an open-label, pragmatic randomized trial that recruited 2859 participants hospitalized with heart failure (regardless of ejection fraction) at 60 hospitals in the United States. Recruitment occurred from June 2018 through March 2022, with follow-up through 30 months for death and 12 months for hospitalizations. The final date for follow-up data collection was July 2022.

Interventions

Loop diuretic strategy of torsemide (n = 1431) or furosemide (n = 1428) with investigator-selected dosage. Main Outcomes and Measures The primary outcome was all-cause mortality in a time-to-event analysis. There were 5 secondary outcomes with all-cause mortality or all-cause hospitalization and total hospitalizations assessed over 12 months being highest in the hierarchy. The prespecified primary hypothesis was that torsemide would reduce all-cause mortality by 20% compared with furosemide.

Results

TRANSFORM-HF randomized 2859 participants with a median age of 65 years (IQR, 56-75), 36.9% were women, and 33.9% were Black. Over a median follow-up of 17.4 months, a total of 113 patients (53 [3.7%] in the torsemide group and 60 [4.2%] in the furosemide group) withdrew consent from the trial prior to completion. Death occurred in 373 of 1431 patients (26.1%) in the torsemide group and 374 of 1428 patients (26.2%) in the furosemide group (hazard ratio, 1.02 [95% CI, 0.89-1.18]). Over 12 months following randomization, all-cause mortality or all-cause hospitalization occurred in 677 patients (47.3%) in the torsemide group and 704 patients (49.3%) in the furosemide group (hazard ratio, 0.92 [95% CI, 0.83-1.02]). There were 940 total hospitalizations among 536 participants in the torsemide group and 987 total hospitalizations among 577 participants in the furosemide group (rate ratio, 0.94 [95% CI, 0.84-1.07]). Results were similar across prespecified subgroups, including among patients with reduced, mildly reduced, or preserved ejection fraction. Conclusions and Relevance Among patients discharged after hospitalization for heart failure, torsemide compared with furosemide did not result in a significant difference in all-cause mortality over 12 months. However, interpretation of these findings is limited by loss to follow-up and participant crossover and nonadherence. Trial Registration ClinicalTrials.gov Identifier: NCT03296813

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FurosemideHeart FailureHumansFemaleMiddle AgedAgedMaleTorsemidePatient DischargeSodium Potassium Chloride Symporter InhibitorsTreatment OutcomeHospitalization

Substanzen

FurosemideTorsemideSodium Potassium Chloride Symporter Inhibitors

Autor:innen und Institutionen

  • Duke Clinical Research Institute, Durham, North Carolina.
  • Department of Medicine, Division of Cardiology, Duke University School of Medicine, Durham, North Carolina.
  • Gillings School of Global Public Health, University of North Carolina at Chapel Hill.
  • Department of Internal Medicine, Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut.
  • Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland.
  • Division of Cardiology, Department of Medicine, University of Michigan, Ann Arbor.

Förderung

  • NHLBI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Mentz, R. J., Anstrom, K. J., Eisenstein, E. L., Sapp, S., Greene, S. J., Morgan, S., Testani, J. M., Harrington, A. H., Sachdev, V., Ketema, F., Kim, D. Y., Desvigne-Nickens, P., Pitt, B., Velazquez, E. J., & TRANSFORM-HF Investigators (2023). Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure. JAMA, 329(3), 214. https://doi.org/10.1001/jama.2022.23924

Vancouver

Mentz RJ, Anstrom KJ, Eisenstein EL, Sapp S, Greene SJ, Morgan S, et al. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure. JAMA. 2023;329(3):214. doi:10.1001/jama.2022.23924

BibTeX
@article{Mentz2023,
  author = {Mentz, Robert J and Anstrom, Kevin J and Eisenstein, Eric L and Sapp, Shelly and Greene, Stephen J and Morgan, Shelby and Testani, Jeffrey M and Harrington, Amanda H and Sachdev, Vandana and Ketema, Fassil and Kim, Dong-Yun and Desvigne-Nickens, Patrice and Pitt, Bertram and Velazquez, Eric J and TRANSFORM-HF Investigators, TRANSFORM-HF Investigators},
  title = {Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure},
  journal = {JAMA},
  year = {2023},
  volume = {329},
  number = {3},
  pages = {214},
  doi = {10.1001/jama.2022.23924}
}
Kostenlos starten →